Trends in Acute Ischemic Stroke Trials Through the 20th Century
暂无分享,去创建一个
D. Liebeskind | S. Starkman | C. Kidwell | S Starkman | J L Saver | D S Liebeskind | C S Kidwell | J. L. Saver | J. Saver
[1] D. Barer. Interpretation of IST and CAST stroke trials , 1997, The Lancet.
[2] W. Koroshetz,et al. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis--not a panacea for ischemic stroke. , 1997, The New England journal of medicine.
[3] K. Lees. Cerestat and other NMDA antagonists in ischemic stroke , 1997, Neurology.
[4] C. Bulpitt. Randomised Controlled Clinical Trials , 1983, Developments in Biostatistics and Epidemiology.
[5] G Bréart,et al. From the Cochrane Library , 2000, Revue d'epidemiologie et de sante publique.
[6] P Sandercock,et al. Reports of randomized trials in acute stroke, 1955 to 1995. What proportions were commercially sponsored? , 1999, Stroke.
[7] R. Collins,et al. Interpretation of IST and CAST stroke trials , 1997, The Lancet.
[8] J. Zivin. Factors determining the therapeutic window for stroke , 1998, Neurology.
[9] J. Marler,et al. Measurements of acute cerebral infarction: a clinical examination scale. , 1989, Stroke.
[10] F. Mahoney,et al. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.
[11] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[12] D. Liebeskind,et al. Acute ischemic stroke trials. , 2001, Stroke.
[13] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[14] K. Lees,et al. Duration of neuroprotective treatment for ischemic stroke. , 1998, Stroke.
[15] P. Easterbrook,et al. Publication bias in clinical research , 1991, The Lancet.
[16] Zheng-Ming Chen,et al. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.
[17] R. Higashida,et al. Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .
[18] V. Torri,et al. Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. , 1989, JAMA.
[19] G. Marchal,et al. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome , 1993, The Lancet.
[20] The Ottawa Stroke Trials Registry Collaborative Group and the development of the Ottawa Stroke Trials Registry (OSTR). , 1994, Controlled clinical trials.
[21] T C Chalmers,et al. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. , 1987, Statistics in medicine.
[22] P. Sandercock. What Questions Can Large, Simple Trials Answer? , 1998, Cerebrovascular Diseases.
[23] George Davey Smith,et al. meta-analysis bias in location and selection of studies , 1998 .
[24] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[25] D. Moher,et al. Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews , 1996, The Lancet.
[26] A. Cohen. Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial. , 1997, Lancet.
[27] P. Bath,et al. Quality of full and final publications reporting acute stroke trials: a systematic review. , 1998, Stroke.
[28] K. Lees,et al. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. , 1999, Stroke.
[29] P. Dorman,et al. Recently Developed Neuroprotective Therapies for Acute Stroke , 1996 .
[30] D. Wade,et al. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. , 2000, Stroke.
[31] Q E Whiting-O'Keefe,et al. Controlled clinical trials. , 1983, The American journal of medicine.
[32] Richard Smith,et al. An amnesty for unpublished trials , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[33] K. Dickersin,et al. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. , 1992, JAMA.
[34] P Sandercock,et al. The Cochrane Collaboration Stroke Review Group. Meeting the need for systematic reviews in stroke care. , 1995, Stroke.
[35] C D Naylor,et al. Incorporating variations in the quality of individual randomized trials into meta-analysis. , 1992, Journal of clinical epidemiology.
[36] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.
[37] D. Moher,et al. Statistical power, sample size, and their reporting in randomized controlled trials. , 1994, JAMA.
[38] P. Fayers,et al. Thirty years of Medical Research Council randomized trials in solid tumours. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).
[39] C. Warlow,et al. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke , 1997, The Lancet.
[40] J D Emerson,et al. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. , 1990, Controlled clinical trials.
[41] P. Dorman,et al. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. , 1996, Stroke.
[42] A. Ahuja,et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .
[43] K. Dickersin,et al. Full publication of results initially presented in abstracts. A meta-analysis. , 1994 .